



sinovac®

EV71 Vaccine Development




Weining Meng

DCVMN 15th Annual General Meeting

29th October, 2014

Sinovac-A leading vaccine company in China



We are:

- 1st company to develop **inactivated hepatitis A** vaccine in China
- 1st company to develop **combined hepatitis A and B** vaccine in China
- 1st company to complete phase I clinical trial on **SARS vaccine** worldwide
- 1st company to develop **H5N1 vaccine** in China
- 1st company to develop and get license of **H1N1 vaccine** worldwide
- 1st** and only Chinese vaccine company listed in Nasdaq

Our Mission

Supply Vaccines To Eliminate Human Diseases

- Provide Chinese Population with International Quality Vaccines
- Provide Vaccines Made in China to Worldwide

Our Products: Hepatitis





Our Products: Influenza



Manufacturing Facilities

Manufacturing Plants

Headquarter- Beijing



Dalian

Vero Cell Cultured Vaccine and Live Attenuated Vaccine




Tangshan



Yi'an Animal Vaccine



Hand Foot Mouth Disease Epidemic



EV71 Epidemic In China




Serious HFMD epidemic in China;

EV71 inducing main serious and fatal cases;

Vaccine against EV71 is the answer.

Development Milestones



Characters of Sinovac EV71 Vaccine

- ✓ Vero Cell, cell factory cultivation technology;
- ✓ H07 strain, C4 subgenotype, isolated by China CDC;
- ✓ Inactivation with formaldehyde
- ✓ Al(OH)₃ as adjuvant
- ✓ 100 u/200u/400 u, 2 doses/3 doses regimen

EV71 Vaccine Clinical Trails

Phase I

- Objective: Safety, Immunogenicity
- Subjects: Babies, children, and Adult
- Dose: 100U、200U、400U

168 subjects

Phase II

- Objective: Immunogenicity, safety
- Subjects: 6-35 months babies
- Dose: 100U、200U、400U

540 subjects

10077 subjects

Phase III

- Objective: Protective effective
- Subjects: 6-35 months babies
- Dose: 400U


Phase III

- Objective: consistency
- Subjective: 6 months-5 years children
- Dose: 400U

1400 subjects


All trials following GCP

inovac®




EV71 Vaccine-Safety

Local Adverse Reactions




Systemic Adverse Reactions





No significant difference between vaccine group and placebo group

EV71 Vaccine-Efficacy



Protection rate for EV71 infection : **94.3%**
Protection for hospitalized cases and serious cases : **100.0%**

EV71 Vaccine-Immunogenicity



56 days after vaccination , Neutralizing antibody positive rate 98.79%、 GMT 165.79 ,
8 months and 14 months after vaccination, high level of antibody
Good immunogenicity and immune persistence.

Industrialization

Total : 29,021 m²
Built-up area : 32,322 m²

Production

19000 m²

Others

4000 m²

Office

9000 m²

2F Animal Lab


1F Biobank

4F Ready for use

3F QC Labs
EV71 Bulk
20 million doses/year

2F Formulation
Filling & Packaging
100 million doses/year

1F Cold Room
1.8 million vials
Utilities



为人类消除疾病提供疫苗

Supply vaccines to eliminate human diseases



sinovac
北京科兴®

谢谢!



让

中国儿童使用国际水平的疫苗
世界儿童使用中国生产的疫苗

Provide Chinese children with international quality vaccines

Provide children in the world with vaccines made in China